AlzeCure Pharma AB (SE:ALZCUR)
:ALZCUR
Want to see SE:ALZCUR full AI Analyst Report?
Top Page
AlzeCure Pharma AB
(ALZCUR)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr1.50
▼(-38.52% Downside)
Action:Reiterated
Date:05/08/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and continued cash burn), which increases reliance on external funding despite low debt. Technicals remain bearish with price below key moving averages and negative MACD, while valuation provides little support due to negative earnings and no dividend yield data.
Positive Factors
Low leverage and balance sheet flexibility
Modest debt and a low debt-to-equity ratio materially reduce near-term refinancing and interest burden risk. For an R&D biotech, low leverage preserves optionality to pursue licensing deals, collaborations or selective financing without immediate solvency pressure.
Negative Factors
No revenue and persistent net losses
Absence of commercial revenue and recurring net losses mean operations depend on external funding. Over months this constrains strategic flexibility, can force dilutive financing, and raises execution risk if capital markets tighten or partnership timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and balance sheet flexibility
Modest debt and a low debt-to-equity ratio materially reduce near-term refinancing and interest burden risk. For an R&D biotech, low leverage preserves optionality to pursue licensing deals, collaborations or selective financing without immediate solvency pressure.
Read all positive factors
AlzeCure Pharma AB (ALZCUR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr160.31M
Dividend YieldN/A
Average Volume (3M)52.87K
Price to Earnings (P/E)―
Beta (1Y)-0.13
Revenue GrowthN/A
EPS Growth-32.29%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.45
Shares Outstanding114,914,450
10 Day Avg. Volume28,042
30 Day Avg. Volume52,872
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
AlzeCure Pharma AB Business Overview & Revenue Model
Company Description
AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biot...
How the Company Makes Money
AlzeCure Pharma AB’s business model is primarily that of an R&D-stage biotech company: it invests in discovery and development of drug candidates and aims to monetize them through partnering transactions rather than product sales (as it does not h...
AlzeCure Pharma AB Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
45
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.27M | -293.00K | -476.00K | -570.00K | -576.00K |
| EBITDA | -48.10M | -35.70M | -37.87M | -55.67M | -77.20M |
| Net Income | -47.65M | -35.23M | -37.17M | -56.04M | -77.78M |
Balance Sheet | |||||
| Total Assets | 59.04M | 34.44M | 32.00M | 70.84M | 45.65M |
| Cash, Cash Equivalents and Short-Term Investments | 50.34M | 31.50M | 29.10M | 25.58M | 41.74M |
| Total Debt | 5.12M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 26.12M | 8.25M | 8.23M | 10.35M | 12.67M |
| Stockholders Equity | 32.92M | 26.18M | 23.77M | 60.48M | 32.97M |
Cash Flow | |||||
| Free Cash Flow | -34.59M | -35.25M | 3.06M | -99.91M | -70.69M |
| Operating Cash Flow | -34.59M | -35.12M | 3.06M | -99.91M | -70.64M |
| Investing Cash Flow | 0.00 | -124.00K | 7.00K | 0.00 | -54.00K |
| Financing Cash Flow | 53.43M | 37.65M | 459.00K | 83.75M | 0.00 |
AlzeCure Pharma AB Technical Analysis
Negative
2.44
Price Trends
1.54
Negative
1.74
Negative
2.24
Negative
Market Momentum
-0.04
Negative
44.38
Neutral
32.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZCUR, the sentiment is Negative. The current price of 2.44 is above the 20-day moving average (MA) of 1.41, above the 50-day MA of 1.54, and above the 200-day MA of 2.24, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.38 is Neutral, neither overbought nor oversold. The STOCH value of 32.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALZCUR.
AlzeCure Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ALZCUR
AlzeCure Pharma AB
1.40
-1.15
-45.14%
ORXOF
Orexo AB
2.10
1.02
94.44%
DE:6FN
Klaria Pharma Holding AB
0.07
<0.01
4.29%
DE:40M
Nanexa AB
0.31
0.13
77.46%
SE:ENZY
Enzymatica AB
2.43
-0.54
-18.18%
SE:ERMA
Enorama Pharma AB
0.45
-2.04
-82.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.